Compare Stocks: ANL, IDYA, ABCL, and GMTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.36 +0.7%	$8.25	$2.74 ▼ $12.58	$3.46B	1.32	10.54 million shs	3.72 million shs
ANL Adlai Nortye	$13.85 +1.6%	$12.36	$0.88 ▼ $17.25	$877.74M	1.04	153,593 shs	77,707 shs
GMTX Gemini Therapeutics	$78.67 +0.0%	$77.27	$1.16 ▼ $14.10	$3.41B	-0.12	189,291 shs	549,435 shs
IDYA IDEAYA Biosciences	$40.17 +0.6%	$37.46	$23.23 ▼ $42.68	$3.51B	-0.07	727,646 shs	765,284 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+0.71%	-7.19%	+94.85%	+78.34%	+180.49%
ANL Adlai Nortye	+1.61%	-8.03%	+6.62%	+25.91%	+673.74%
GMTX Gemini Therapeutics	+0.03%	-4.54%	+2.17%	+11.83%	+31.90%
IDYA IDEAYA Biosciences	+0.55%	-3.39%	+13.47%	+37.47%	+57.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.36 +0.7%	$8.25	$2.74 ▼ $12.58	$3.46B	1.32	10.54 million shs	3.72 million shs
ANL Adlai Nortye	$13.85 +1.6%	$12.36	$0.88 ▼ $17.25	$877.74M	1.04	153,593 shs	77,707 shs
GMTX Gemini Therapeutics	$78.67 +0.0%	$77.27	$1.16 ▼ $14.10	$3.41B	-0.12	189,291 shs	549,435 shs
IDYA IDEAYA Biosciences	$40.17 +0.6%	$37.46	$23.23 ▼ $42.68	$3.51B	-0.07	727,646 shs	765,284 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+0.71%	-7.19%	+94.85%	+78.34%	+180.49%
ANL Adlai Nortye	+1.61%	-8.03%	+6.62%	+25.91%	+673.74%
GMTX Gemini Therapeutics	+0.03%	-4.54%	+2.17%	+11.83%	+31.90%
IDYA IDEAYA Biosciences	+0.55%	-3.39%	+13.47%	+37.47%	+57.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.71	Moderate Buy	$12.83	12.97% Upside
ANL Adlai Nortye	2.67	Moderate Buy	$24.25	75.09% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
IDYA IDEAYA Biosciences	2.83	Moderate Buy	$50.19	24.94% Upside

Current Analyst Ratings Breakdown

Latest ANL, IDYA, ABCL, and GMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	IDYA IDEAYA Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/1/2026	IDYA IDEAYA Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/1/2026	IDYA IDEAYA Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$42.00
8/11/2026	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$12.00 ➝ $30.00
8/6/2026	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $9.00
8/6/2026	ABCL AbCellera Biologics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $12.00
8/5/2026	IDYA IDEAYA Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$58.00 ➝ $60.00
8/5/2026	IDYA IDEAYA Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$63.00 ➝ $59.00
7/17/2026	ABCL AbCellera Biologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IDYA IDEAYA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	ANL Adlai Nortye	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	46.36	N/A	N/A	$2.92 per share	3.89
ANL Adlai Nortye	$5M	178.39	N/A	N/A	$3.34 per share	4.15
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
IDYA IDEAYA Biosciences	$218.71M	16.14	N/A	N/A	$13.65 per share	2.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	11/5/2026 (Estimated)
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
IDYA IDEAYA Biosciences	-$113.70M	-$1.94	N/A	N/A	N/A	-75.93%	-16.73%	-15.34%	11/9/2026 (Estimated)

Latest ANL, IDYA, ABCL, and GMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million
8/4/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.06	-$1.22	-$0.16	-$1.22	$8.02 million	$8.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
ANL Adlai Nortye	0.04	9.55	0.65
GMTX Gemini Therapeutics	N/A	71.49	71.49
IDYA IDEAYA Biosciences	N/A	10.45	10.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
ANL Adlai Nortye	35.21%
GMTX Gemini Therapeutics	75.42%
IDYA IDEAYA Biosciences	98.29%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
ANL Adlai Nortye	N/A
GMTX Gemini Therapeutics	12.90%
IDYA IDEAYA Biosciences	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	306.61 million	219.53 million	Optionable
ANL Adlai Nortye	127	64.40 million	N/A	Not Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
IDYA IDEAYA Biosciences	80	87.86 million	83.73 million	Optionable

ANL, IDYA, ABCL, and GMTX Headlines

Recent News About These Companies

Bank of New York Mellon Corp Takes Position in IDEAYA Biosciences, Inc. $IDYA

2 hours ago | marketbeat.com

Citizens Jmp Reiterates Market Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA)

3 hours ago | americanbankingnews.com

The Manufacturers Life Insurance Company Takes Position in IDEAYA Biosciences, Inc. $IDYA

September 2 at 4:39 AM | marketbeat.com

Citizens Jmp Reaffirms Market Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA)

September 1 at 9:59 AM | marketbeat.com

IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences

September 1 at 6:00 AM | prnewswire.com

IDEAYA Bioscience Advances IDE849 Toward Phase 3 Trial Following FDA Meeting

August 31 at 9:25 AM | rttnews.com

IDEAYA Biosciences Plans Phase 3 Trial for Lung Cancer Therapy

August 31 at 9:25 AM | finance.yahoo.com

IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in ...

August 31 at 9:25 AM | finance.yahoo.com

IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

August 31 at 6:00 AM | prnewswire.com

Man Group plc Purchases New Shares in IDEAYA Biosciences, Inc. $IDYA

August 29, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Buys New Shares in IDEAYA Biosciences, Inc. $IDYA

August 29, 2026 | marketbeat.com

IDEAYA Biosciences Announces Inducement Grants To Newly Hired Employees

August 28, 2026 | rttnews.com

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 28, 2026 | prnewswire.com

BlackRock Inc. Makes New Investment in IDEAYA Biosciences, Inc. $IDYA

August 27, 2026 | marketbeat.com

Deutsche Bank AG Invests $3.50 Million in IDEAYA Biosciences, Inc. $IDYA

August 27, 2026 | marketbeat.com

Odyssean LLC Buys 87,308 Shares of IDEAYA Biosciences, Inc. $IDYA

August 26, 2026 | marketbeat.com

Jupiter Topco LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA

August 26, 2026 | marketbeat.com

IDEAYA Biosciences (NASDAQ:IDYA) Hits New 12-Month High - Here's Why

August 25, 2026 | marketbeat.com

Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform

August 25, 2026 | seekingalpha.com

Mitsubishi UFJ Asset Management Co. Ltd. Purchases Shares of 59,780 IDEAYA Biosciences, Inc. $IDYA

August 22, 2026 | marketbeat.com

Great Lakes Advisors LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA

August 21, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL, IDYA, ABCL, and GMTX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$11.36 +0.08 (+0.71%)

Closing price 09/2/2026 04:00 PM Eastern

Extended Trading

$11.39 +0.03 (+0.25%)

As of 05:32 AM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Adlai Nortye NASDAQ:ANL

$13.85 +0.22 (+1.61%)

Closing price 09/2/2026 04:00 PM Eastern

Extended Trading

$14.16 +0.32 (+2.27%)

As of 09/2/2026 07:30 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Gemini Therapeutics NASDAQ:GMTX

$78.67 +0.02 (+0.03%)

As of 09/1/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

IDEAYA Biosciences NASDAQ:IDYA

$40.17 +0.22 (+0.55%)

Closing price 09/2/2026 04:00 PM Eastern

Extended Trading

$40.16 -0.02 (-0.04%)

As of 04:28 AM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, IDYA, ABCL, and GMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, IDYA, ABCL, and GMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, IDYA, ABCL, and GMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL, IDYA, ABCL, and GMTX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Adlai Nortye NASDAQ:ANL

Gemini Therapeutics NASDAQ:GMTX

IDEAYA Biosciences NASDAQ:IDYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, IDYA, ABCL, and GMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, IDYA, ABCL, and GMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, IDYA, ABCL, and GMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL, IDYA, ABCL, and GMTX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Adlai Nortye NASDAQ:ANL

Gemini Therapeutics NASDAQ:GMTX

IDEAYA Biosciences NASDAQ:IDYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools